FOR RESEARCH USE ONLY!

rev 06/21

Anti-TNF-α (Certolizumab), Humanized Antibody

CATALOG NO.: A2142-100 (100 µg)

BACKGROUND DESCRIPTION: The research-grade biosimilar is a humanized TNF-α monoclonal antibody. The original monoclonal antibody (Certolizumab pegol (CZP)) consists of polyethylene glycol conjugated to the antigen-binding fragment of the humanized monoclonal antibody. The antibody targets and neutralizes soluble and membrane forms of tumor necrosis factor-alpha (TNF-α) and inhibits TNF-α mediated signaling in vitro. Unlike other TNF inhibitors, this antibody does not contain the Fc region. As a result, decreased Fc-mediated effects such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) are observed. The original monoclonal antibody received FDA approval to treat moderate to severe rheumatoid arthritis, Crohn’s disease, ankylosing spondylitis, and psoriatic arthritis.

TNFSF2, TNF-alpha, TNFA, TNF-α, TNFα ALTERNATE NAMES:

ANTIBODY TYPE: Monoclonal

HOST/ISOTYPE: Recombinant / Fab-IgG1-kappa

SOURCE: CHO cells

IMMUNOGEN: Human TNF-α

FORM: Liquid

FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -80 ºC. Avoid repeated freeze-thaw cycles

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS: Anti-TNF-α (Adalimumab), humanized Antibody (Cat. No. A1048) Anti-TNF alpha (Infliximab), Human IgG1 Antibody (Cat. No. A1097) Anti-TNF alpha (Humicade), Human IgG4 Antibody (Cat. No. A1093) Anti-EGFR (Cetuximab), Chimeric Antibody (Cat. No. A1047) Anti-EGFR (Matuzumab), Human IgG1 Antibody (Cat. No. A1090)

FOR RESEARCH USE ONLY! Not to be used on humans.

155 S. Milpitas Blvd., Milpitas, CA 95035 USA | T: (408)493-1800 F: (408)493-1801 | www.biovision.com | [email protected]